SIGA

SIGA Technologies, Inc. - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the development and sale of TPOXX® (tecovirimat), an antiviral drug for the treatment of smallpox. The company primarily serves the U.S. Government (via BARDA and DoD contracts) and international governments. As of March 31, 2026, the company had 71,724,097 shares of common stock outstanding.

Key Financial Metrics

Note: The increase in total liabilities is primarily driven by a $43.0 million dividend payable declared in March 2026.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by approximately 11% to $6.24 million. This was driven by a lack of international sales in Q1 2026 compared to $5.8 million in international sales in Q1 2025. However, U.S. government R&D revenue increased from $1.2 million to $2.7 million.
• Increased Loss: Net loss widened significantly to $3.45 million from $0.41 million. This was due to higher operating expenses, specifically a $2.8 million increase in Cost of Sales (driven by IV TPOXX® delivery and technology transfer costs) and increased R&D expenses related to the EMA referral procedure.
• Cash Flow Reversal: Operating cash flow swung from a positive $7.1 million in Q1 2025 to a negative $8.7 million in Q1 2026. The outflow was primarily due to inventory build-up ($7.4 million) and a lack of large receivable collections seen in the prior year.
• Dividend Declaration: The Board declared a special cash dividend of $0.60 per share ($43.9 million total) in March 2026, creating a significant current liability.

Outlook, Risks, and Management Commentary

• Regulatory Update (Mpox): The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion in March 2026 recommending that Tecovirimat-SIGA no longer be used for the treatment of mpox, based on clinical trial results (PALM 007, STOMP, UNITY) that did not meet primary endpoints. The product retains approval for smallpox, cowpox, and vaccinia complications. The UK MHRA has requested label alignment.
• Contract Status: The 19C BARDA Contract remains the primary revenue driver, with a total potential value of approximately $630 million. As of March 31, 2026, $450.2 million of oral TPOXX® has been delivered and accepted.
• Future Pipeline: The company is targeting a Supplemental NDA submission to the FDA within the next 12 months for a smallpox post-exposure prophylaxis (PEP) indication.
• Liquidity: Management believes current cash resources ($145.6 million) are sufficient to meet requirements for at least the next 12 months.
• Risks: Key risks include the impact of the EMA mpox recommendation on international commercialization, potential tariff impacts on IV TPOXX® manufacturing costs, and reliance on U.S. government contracts.

Investor Verification Checklist

• Dividend Impact: Verify the cash outflow timing for the $43.9 million special dividend declared in March 2026 (paid April 23, 2026) and its impact on future liquidity.
• International Sales Outlook: Assess the impact of the EMA mpox recommendation on future international sales, given the absence of international revenue in Q1 2026.
• Inventory Valuation: Review the $56.5 million inventory balance, noting the significant increase in Work-in-Process ($49.1 million), to ensure alignment with future delivery schedules under the BARDA contract.
• BARDA Contract Execution: Monitor the exercise of remaining unexercised options ($5.6 million) and the timeline for the remaining $545.2 million in exercised options.
• PEP Submission: Track progress toward the targeted Supplemental NDA submission for smallpox PEP within the next 12 months.